组织芯片研究胃食管黏膜病变中Ki67和C-erbB-2的表达及意义

Investigation of Ki67 and C-erbB-2 expression in esophagogastric disease and their significances by tissue microarray

目的:研究Ki67和C-erbB-2在各类胃食管黏膜病变中的表达及意义.方法:采用TMA制作140例各类胃食管黏膜病变的组织芯片,分成Barrett食管(BE)组、贲门癌(CA)组、食管腺癌(EA)组、和胃窦肠化(AIM)组、贲门肠上皮化生(CIM)组和正常对照(Control)组,共6组,采用免疫组织化学方法检测Ki67和C-erbB-2的表达.结果:BE组,EA组和CA组Ki67的阳性率均显著高于Control组(40.9%,69.6%,61.9%vs0.0%,均P<0.01),明显高于CIM组11.5%(P<0.05);CIM组和AIM组以及EA组和CA组之间无显著性差异;EA和CA组中Ki67的阳性率高于BE组(P<0.05);BE组,EA组和CA组C-erbB-2的阳性率均显著高于Control组和CIM组(31.8%,52.1%,52.4%vs0.0%,P<0.01),明显高于AIM组3.6%(P<0.05).C-erbB-2与Ki67在各类胃食管黏膜病变组织中的表达统计学上具有紧密关联性(P=0.001).结论:Ki67和C-erbB-2可能在Barrett食管和胃食管连接处腺癌的发生发展中起重要的促进作用.

AIM： To detect the expression of Ki67 and C-erbB-2 in esophagogastric mucosal diseases and conclude their significances. METHODS： Using tissue microarray technique （TMA）, 140 specimens of mucosa at esophagogastric junction were divided into 6 groups Barrett’s esophagus （BE） group, cardiac adenocarcinoma （CA） group, esophageal adenocarcinoma （EA） group, antrum intestinal metaplasia（AIM） group, cardia intestinal metaplasia （CIM） group, and normal control （NC） group. Ki67 and C-erbB-2 expression were examined by immunohistochemistry （IHC）. RESULTS： The positive staining of Ki67 in BE, EA or CA group was significantly higher than that in NC group （40.9%, 69.6%, 61.9% vs 0.0%; all P 〈 0.01）, even than that （11.5%） in CIM group （P 〈 0.05）. Ki67 expression was not markedly different between CIM and AIM group as well as between EA and CA group, but the positive rate of Ki67 expression in EA and CA group was higher than that in BE group （P 〈 0.05）. The positive staining of C-erbB-2 in BE, EA or CA group was significantly higher than that in NC, CIM or AIM group （31.8%, 52.1%, 52.4% vs 0.0%, 0.0%, 3.6%; P 〈 0.01 or P 〈 0.05）. McNemar’s test showed a significant correlation between Ki67 and C-erbB-2 expression in these diseases at esophagogastric junction （P = 0.001）. CONCLUSION： Ki67 and C-erbB-2 may play stimulative roles in the occurrence and development of Barrett’s esophagus and adenocarcinoma at the esophagogastric junction.